Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.

Frontiers in endocrinology - 1 Jan 2026

Yamin Tzahi, Cohen Oded, Robenshtok Eyal, Izkhakov Elena, Miodovnik Mor, Gutfeld Orit, Leshem Yasmin, Meirovitz Roman, Warshavsky Anton, Muhanna Nidal, Finkel Inbar

Abstract excerpt

Objective: BRAF V600E mutation is the most common and clinically significant genetic alteration in advanced thyroid cancers. This study provides real-world experience with BRAF and MEK inhibitors other than dabrafenib and trametinib in the treatment of advanced thyroid cancers harboring this mutation. Methods: A case series of four patients with advanced thyroid cancer (three papillary and one anaplastic) treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oximes

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Share to Pyrimidinones

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41727688
DOI: 10.3389/fendo.2026.1694805
PMCID: PMC12916350

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.PMID 41727688Read ↗

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.Semantic proximity Read ↗

Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.Semantic proximity Read ↗

Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres.Semantic proximity Read ↗

Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.Semantic proximity Read ↗

A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancerSemantic proximity Read ↗

Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer.Semantic proximity Read ↗

Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.Semantic proximity Read ↗

Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.Semantic proximity Read ↗

Targeted therapy in thyroid cancer: molecular alterations and clinical management.Semantic proximity Read ↗

Combination therapy with BRAF and MEK inhibitors for anaplastic thyroid cancer: A report of two cases.Semantic proximity Read ↗

Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment StrategySemantic proximity Read ↗

Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.